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Anti-tumour activity of photodynamic therapy in combination with
mitomycin C in nude mice with human colon adenocarcinoma
LW Ma, J Moan, HB Steen and V lani
Department ofBiophYsics, The Institute ofCancer Research, Montebello, 0310 Oslo 3, NorKay.
S_ry The interaction of photodynamic therapy (PDT) and a chemotherapeutic drug, mitomycin C
(MMC), was investigated using WiDr human colon adenocarcinoma tumours implanted on Balb/c athymic
nude mice. The WiDr tumours were treated with PDT alone, MMC alone or with both. It was found that the
combined treatment produced a greater retardation in the growth of the WiDr tumour than monotherapy with
MMC or PDT. The synergistic effect was especially prominent when PDT was used in combination with a low
dose of MMC (1 mglkg-'), since treatment of I mg kg-' MMC alone had no effect on the tumour. The
anti-tumour activity of PDT was found to be increased with MMC of 5 mg kg-'. The response of normal skin
on mice feet to PDT slightly greater when PDT was combined with 5 mg kg-' MMC than when PDT was
applied alone, while no detectable additional effect on skin photosensitivity was observed when PDT was
combined with I mg kg- ' MMC. An enhanced uptake of Photofrin in tumours was found 12 h and 24 h after
administration of MMC. The effect of MMC on the cell cycle distribution of cell dissociated directly from the
tumours was studied. The results suggest that the increased susceptibility to photoinactivation of Photofrin-
sensitised tumours may be due to MMC-induced accumulation of the tumour cells in S-phase.
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In the last decade, it has been demonstrated that photo-
dynamic therapy (PDT) can be used for the treatment of
many forms of cancer (Dougherty et al., 1990; Henderson,
1990). In order to enhance the efficiency of this therapy,
many expenmental approaches and clinical investigations
have shown that combinations of PDT with other treatments,
such as hyperthermia (Henderson et al., 1985), ionising radia-
tion (Kostron et al., 1986), electric current (Ma et al., 1993a),
chemotherapeutic drugs (Cowled et al., 1987; Edell and Cor-
tese, 1988; Jin et al., 1992), immunological agents (Dima et
al., 1990) or surgical operations (Vietri et al., 1991), produce
significant advantages and may become beneficial modalities
in clinical treatment of cancer.
It is known that PDT in combination with chemotherapy
is a promising therapy. With combination treatment not only
can the efficacy of cancer treatment be increased, but the
dose of photosensitiser and chemotherapeutic drug can also
be decreased, thus leading to a reduction in adverse side-
effects. Several studies have demonstrated that the effects of
PDT can be potentiated by chemotherapeutic agents such as
doxorubicin and methotrexate in vivo (Cowled et al., 1985a;
Edell and Cortese, 1988). PDT combined with anti-cancer
drugs (bacillus Calmette-Guerin and misonidazole) enhances
the anti-tumour activity of either therapy used alone (Gon-
zalez et al., 1986; Cho et al., 1992). Glucocorticoids
administered after PDT greatly potentiate the therapeutic
effect, as shown by the reduced rate of recurrence of the
tumours (Cowled et al., 1985b). However, so far there are
few reports exploring the mechanism of interaction between
PDT and chemotherapeutic drugs. Some investigators have
proposed that the enhanced effect of PDT combined with
certain chemotherapeutic drugs may be associated with the
sum of the damage induced by both modalities and with the
cytotoxic effect of the drugs on capillaries, thereby inhibiting
their recovery from damage caused by PDT (Cho et al.,
1992). For example, the potentiation of PDT with haemato-
porphyrin derivatives (HPD) by doxorubicin may be because
(a) both doxorubicin and HPD accumulate in mitochondria
(Berns et al., 1982) and both doxorubicin and PDT form
toxic oxygen radicals (Handa and Sato, 1975; Moan et al.,
1979); or (b) doxorubicin is known to affect the growth of
various solid tumours and may cause sufficient injury to
result in death of cells sublethally damaged by PDT (Beilnier
and Lin, 1985).
Recently, several reports have shown a synergism between
PDT and bioreductive drugs (Henry and Isaacs, 1989; Brem-
ner et al., 1992; Baas et al., 1994). The rationale behind the
combination of PDT and bioreductive drugs is to exploit the
tumour hypoxia induced by PDT in order to activate the
cytotoxic action of these drugs (Hirsch et al., 1987). Mito-
mycin C (MMC) is a bioreductive drug and a well-known
chemotherapeutic agent widely used for treatment of various
types of cancer (Wakaki et al., 1958; Verweij and Pinedo,
1990). A study by Baas et al. (1994) has revealed that com-
bining PDT with MMC greatly improves the tumour re-
sponse. Our previous work in vitro has shown that the intra-
cellular uptake of Photofrin by WiDr cells (a human colon
adenocarcinoma cell line) is increased by addition of MMC
(Ma et al., 1992a), and that the cytotoxicity of PDT is
significantly enhanced by MMC (Ma et al., 1993b).
Moreover, it has been found that the sensitivity of cells to
PDT can be increased by MMC by causing an increase in the
fraction of cells in S-phase of the cell cycle before PDT (Ma
et al., 1993b). In view of these in vitro results, it is of interest
to use the same tumour model (WiDr) in vivo to investigate
these aspects ofcombination therapy. Questions addressed by
this research include:
(1) can MMC act synergistically with PDT to inhibit
tumour growth?
(2) is there a correlation between the effect of MMC on
cell cycle distribution of tumour cells in vivo and the
ability of MMC to potentiate PDT?
(3) has MMC any influence on the uptake of Photofrin by
the tumour tissues?
Materials and methods
Chemicals
Photofrin was a kind gift from Quadra Logic Technologies
(Vancouver, Canada). Mitomycin C (MMC) was obtained
from Medac (Hamburg, Germany).
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Female Balb/c athymic nude mice were purchased from
Bomholt Gaard, Ry, Denmark. At the start of the experi-
ments, the mice were 7-8 weeks old, weighing 18-20 g.
Three mice were housed per cage with autoclaved filter
covers in a room with subdued light at constant temperature
(24-26"C) and humidity (30-50%). Food and bedding were
sterilised and the mice were given tap water ad libitwn in
sterilised bottles. Approximately 5 x 106 WiDr cells (a human
colon adenocarcinoma cell line) suspended in 0.04 ml of
phosphate-buffered saline (PBS) were implanted subcutan-
ously on the dorsal side of the foot of the right hind limb of
each mouse. At this site the tumour was easily accessible to
treatment and to assessment of response.
The mice were assessed regularly and the tumour size was
measured along three orthogonal diameters (Dl, D2, D3),
every second day using a caliper. The volume was calculated
assuming spheroidal geometry:
Vol = (x/6) DI x D2 x D3
When the tumours reached 75-100mm3 the mice were
injected intraperitoneally with MMC and/or Photofrin and
irradiated 24 h later.
Tumour response
After irradiation each tumour was measured three times a
week and the results from each experimental group were
pooled to give a mean growth curve. In the initial phase the
sizes of all tumours were measured and averaged each day
and the mean volume was plotted ± s.e. (vertical bar). Once
steady regrowth was established the analysis was changed:
the time taken to reach fixed sizes was determined for each
mouse and the mean time was plotted ± s.e. (horizontal bar).
The use of the average time to a fixed end point (horizontal
averaging) avoids ambiguities about growth rates which may
result from variable latency periods. A similar measuring
method was used previously by Evensen and Moan (1987).
The tumour response was further evaluated as the tumour
growth time, i.e. the time required for a tumour to reach a
volume five times that on the day of light exposure. The
exponential regrowth phase was evaluated as the tumour
doubling time when passing five times treatment volume.
These calculations were based on growth curves for each
individual tumour.
Normal tissue response
The skin of sensitised mice rapidly became oedematous on
exposure to light. This change was assessed by measuring the
thickness of a treatment-induced oedema in the right hind
limb of mice without tumours. These mice were otherwise
treated as those bearing tumours. After irradiation the thick-
ness (Tt) of the treated and (T.) of the untreated foot was
measured about three times a week for 35 days. The normal
tissue response was calculated as (TLTJ)- 1, giving the value
0 for unirradiated tissue and 1 for a doubling in foot thick-
ness.
Temperature measurements
Temperature on the surface of tumours was measured by
using a thin copper-constantan thermocouple (KM 457 x P,
Kane-May, UK).
Irradiation
Unanaesthetised mice were placed in Lucite jigs with the
tumour-bearing leg loosely fixed with tape without impairing
the blood flow to the foot. The tumour was then exposed to
red light from a rhodamine 6G dye laser (Spectra Physics
375) pumped by an argon ion laser (Spectra Physics 164).
The dye laser was tuned at 630 ± 5 nm as controUled by
means of a Jarrel Ash monochromator. The laser beam was
defocused by means of a microscope eyepiece. The fluence
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rate at the position of the tumour was measured with a
calibrated thermopile (YSI Kettering model 65A radiometer)
and maintained at 150 mW cm-2 The exposure time was
15min, corresponding to an exposure of 135 Jcm2.
Determination ofPhotofrin concentration in tumour tissue
Twenty-four hours after injection of Photofrin and Photofrin
plus MMC (see Results), the mice were killed and the levels
of Photofrin in tumours were measured. The method of
determining the concentration of Photofrin in tissues has
been described previously (Ma et al., 1992h). Briefly, tissue
was made into a sL ,pension by means of an Ystral mechani-
cal homogeniser (J)ottingen, Germany). A solution of 1%
sodium dodecyl sulphate (SDS) in I N perchloric acid-
methanol (1:1, v/v) was chosen to bnrng the maximum
amount of Photofrin into the supernatant (Gomer et al.,
1985; Peng et al., 1987).
After homogenisation, the samples were frozen, thawed,
sonicated for 30 s, diluted 1:50 in the same solvent, sonicated
once more, centrifuged at 1600g for 10 min and, finally, the
supernatants were collected. Approximately 75% of Photo-
frin from the tissue suspension can be extracted with this
method (Peng et al., 1987).
Drug levels in the supernatants were quantitatively deter-
mined by recording fluorescence emission spectra of the sam-
ples using a Perkin-Elmer LS 50 B Luminescence spectro-
meter connected to a personal computer. The excitation
wavelength was 404 nm, the slit width corresponded to a
resolution of 5.0 nm and the emission wavelength was scan-
ned from 550 to 700 nm. The background fluorescence from
control samples was subtracted. Photofrin levels in the sam-
ples were determined by adding a known amount of the
drug, similar to that already present in the extraction
medium, and recording the emission spectra once more.
Measurement ofcell cycle distribution
After different treatments (PDT and/or MMC), the mice
were killed and the tumours were excised and minced. Single-
cell suspensions were prepared by a 1 h disaggreption using
a modified enzyme cocktail containing 0.05% pronase and
0.2% collagenase (Brown et al., 1979). The viability of these
cells after this enzymatic digestion procedure was >94% as
estimated by trypan blue exclusion. For testing the cell cycle
distribution of dead cells inactivated by the treatment of
single or combined therapy, the cells were washed once in a
buffer [10 mM magnesium chloride, 100 mM sodium chloride,
10 mM Tris (hydroxymethyl)amino-methane, pH 7.3] after
the preparation of a single-ell suspension and stained with
201Lgmm1' mithramycin (a DNA-specific dye for dead cells)
dissolved in the same buffer. This dye (mithramycin) does not
permeate the membrane of vital cells, leaving only dead cells
with fluorescence. The DNA histograms were measured
immediately after staining by a laboratory-built flow
cytometer described elsewhere (Steen, 1986). For determining
the effect of MMC alone on the distribution of the stage of
the cell cycle of the tumour cells, the single-cell suspension of
cells was fixed in 10 ml of ice-cold 70% ethanol. After
fixation the cells were washed once in the same buffer as
mentioned above and incubated with 1OOILgmlmL mith-
ramycin. The DNA histograms were recorded on an Argus
100 flow cytometer (Skatron, Tranby, Norway). A minimum
of 20000 cells were measured for each analysis.
Results
Effect ofMMC on the retardation ofthe cell cycle ofthe
tumour cells
The percentage of ceUs in S-phase of the ceUl cycle was
determined by flow cytometry (Table I). At different times
after the injetion of MMC into the mice, ceUls were dis-
sociated directly from the tumours. The table shows that..a i-our aci_ t o PDT rsu6C.m wiS MC
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addition of MMC (1 mg kg-' or 5 mgkg-') can result in an
increase in the fraction of the tumour cells in S-phase. When
lmgkg-' or Smgkg-' MMC was given i.p. for 12h and
24 h respectively, the number of cells in S-phase was
enhanced by a factor of 2.4 and 2.3. DNA histograms are
shown for cells treated with I mg kg-' MMC for 12 h and
5 mg kg-' MMC for 24 h (Figure 1). In these histograms, the
peak with lower fluorescence values is due to the GI phase of
the roughly 50% diploid host cells found in the WiDr
tumours (Siemann et al., 1981), while the peak with about
1.6-fold higher DNA content represents the GI phase of the
aneuploid WiDr tumour cells with their S and G2/M phases
at correspondingly higher fluorescence (Siemann and Keng,
1986). Figure 1 shows a relative increase in the number of
S-phase cells after addition of MMC (1 mg kg-' and 5 mg
kg-') compared with the control sample. The quantitative
analysis of the histograms was carried out by means of the
computer progam ModiFit (Verity Software House, Top-
sham, ME, USA).
TabeI Effects on the percentage of tumour cells in S-phase of the
cell cycle at different times after injection of mitomycin C into the
mice
Percentage of cells in S-phase
Sample I mgkg- 5mgkg-'
Control (without MMC) 13.7 ± 3.6 (1.0)
MMC
30 min 16.8 (1.2) 16.3 (1.2)
2h 15.3 (1.1) 17.6 (1.3)
6h 19.9 (1.5) 18.1 (1.3)
12 h 32.3 (2.4) 26.8 (2.0)
24h 19.2 (1.4) 31.1 (2.3)
The percentage of tumour cells in S-phase was obtained by
measuring the elular DNA content with flow cytometry (FCM).
Each value is based on the measurement of 20 000 cells. The
numbers in parentheses are values normalised to unity for the
control sample (without MMC). The mice were injected with i.p.
MMC 30 min, 2 h, 6 h, 12 h and 24 h before they were killed. The
treated tumours were removed to make single-cell suspensions and
the tumour cells were fixed with 70% ethanol and stained with
mithramycin before measurement by FCM. For the control sample,
the number is represented as mean ± s.d.
Susceptibility ofthe tumour cells in different phases ofthe cell
cycle to the killing effect ofsingle and combined treatment
Table II shows the cell cycle distribution of dead cells after
single or combined treatment. All samples were collected 4 h
after completion of each treatment as indicated in Table II.
After treatment with MMC alone, no apparent change in the
distribution of the stages of the cell cycle was found, while
treatment with PDT alone appeared to result in a slightly
increased fraction of cells inactivated in S-phase (Table II).
When I mg kg-' MMC was administered i.p. 12 h after the
injection of Photofrin (20 mgkg-'), followed 12 h later by
irradiation, the fraction of dead cells in S-phase and G2JM
phase was enhanced by a factor of 1.8 and 1.7 respectively.
When 5 mgkg-' MMC and Photofrin (20mg kg-') were
given simultaneously for 24 h followed by irradiation, the
fraction ofdead cells in S and Gj/M phases was increased 2.3
Table H The cell cycle distribution of dead cells after treatment
with MMC and PDT separately and in combination
Samnpe Go/G, S G2/M
Control 74.9 (1.0) 17.8 (1.0) 7.3 (1.0)
MMC 1 mgkg-' 77.8 (1.0) 16.2 (0.9) 6.0 (0.8)
MMC 5mgkg-' 73.9 (1.0) 17.7 (1.0) 8.3 (1.1)
PDT 70.9 (0.9) 22.2 (1.3) 7.1 (1.0)
MMC Img kg-'+PDT 57.1 (0.8) 30.0 (1.8) 12.9 (1.7)
MMC 5mglkg-'+PDT 44.1 (0.6) 41.2 (2.3) 14.7 (2.0)
The cell cycle distribution of the dead cells was obtained by
measuring their DNA content with flow cytometry. Four hours after
each treatment the tumours treated were collected, made into
single-cell suspensions and then stained with mithramycin, which
does not stain vital cells. Hence, the DNA histogram of the
preparation was that of dead cells only. In the table each number is
based on the measurement of 20 000 cells. The numbers in
parentheses are values nonnalised to unity for the control sample
(without MMC). MMC alone: 1 mg kg-' or 5 mg kg-' MMC was
injected i.p. into the mice for 12h or 24h followed 4h later by
sample collection. PDT alone: the mice were given i.p. 20mgkg-'
Photofrin for 24 h followed by irradiation. PDT combined with
MMC: the mice were injected with I mgkg-' MMC 12h after
administration of 20mg kg-' Photofrin, followed 12 h later by
irradiation, while 5 mg kg-' MMC and 20mg kg-' Photofrin were
given simultaneously for 24 h followed by irradiation.
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DNA-associated fluorescence (rel. units)
F-ige 1 DNA histograms of WiDr tumour cells after the injection (i.p.) of 1 mg kg-' MMC for 12 h and 5 mg kg- ' MMC for
24 h. The first peak with low fluorescence values represents the diploid host cels from the tumour-bearing mice. The bimodal distribution at higher fluorescence values represents the aneuploid neoplastic cels (see Results). The experimental conditions are
described in Table I.
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Fugue 2 DNA histograms of dead cells caused by single or combined treatment as described in Table II. The experimental
conditions are described in Table II.
and 2.0 times respectively compared with control samples
(Table II). The corresponding DNA histograms are shown in
Figure 2. For PDT treatment, the proportion of dead cells in
the sample as measured by flow cytometry was approx-
imately 13%. For PDT combined with MMC, the proportion
of dead cells measured was about 20%.
In addition, when all of the tumour samples were collected
8 h after finishing the treatments as indicated in Table II, the
results were similar to those shown in Table I, but with a
smaller increase in the fraction of dead cells in S-phase and
G2/M phase after the combined treatment (data not shown).
Effect ofMMC on Photofrin uptake by the twnours
The effect of MMC on the uptake ofPhotofrin in the tumour
tissues is shown in Figure 3. This figure depicts the concen-
trations of Photofrin in tumours relative to that of a sample
with Photofrin only at different times after the injection of
1 mg kg-' or 5 mgkg' MMC. For all samples, Photofrin
concentrations in tumours were measured 24 h after injection
of the drug. Figure 3 shows that when the mice were given
either 1 mg kg-' or 5 mg kg-' MMC for 30min followed by
24 h administration of Photofrin, there was a slight increase
in Photofrin uptake by the tumours. Moreover, the uptake of
Photofrin by the tumours was increased 1.5-fold over the
control sample (Photofrin only), when 1 mgkg-' MMC was
injected at 12 h after Photofrin administration for a further
12 h and 1.6-fold when 5 mg kg-' MMC plus Photofrin were
given simultaneously for 24 h (Figure 3).
Effect ofsingle or combined treatment on tumour growth
Figure 4 shows the growth curves of the WiDr tumour after
MMC and/or PDT. It can be seen that 1 mg kg-' MMC
alone had no effect on the tumour growth, while 5 mgkg-'
MMC alone had a slight retarding effect. Tumour growth in
mice given light alone and MMC plus light did not differ
significantly from the growth of control tumours (no sen-
sitiser, no light) (data not shown). When the mice were
injected i.p. with a non-toxic dose of MMC (1 mg kg-') 12 h
after the injection of Photofrin (20mg kg-') and followed
12 h later by irradiation, a synergistic retarding effect of the
two treatments on the growth of the tumour was observed,
while concomitant administration of MMC (5 mg kg-') and
Photofrin (20mg kg-') for 24h followed by irradiation also
resulted in a significantly increased anti-tumour effect of the
two treatments (Figure 4 and Table III). However, PDT
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Fug 3 The effect of MMC on the uptake of Photofrin in the
tumours. Each mouse was injected i.p. with 20mg kg-' Photofrin
and was killed 24 h later for the measurement of Photofrin
uptake. At the following time points, -6, -2, -0.5, 0, + 12 h
(relative to injection of Photofrin at zero time), the mice received
i.p. injection of MMC lmglkg-' (A) or 5mgkg-I (-). The
numbers on the ordinate are values normalised to unity for the
sample with Photofrin only (0). Each bar represents the
mean ± s.d. of five independent samples.
combined with MMC did not significantly change the
tumour doublng time in the regrowth phase (Table III).
A slight increase in temperature (<40-C) in the tumours
during light exposure was found, but it did not affect the
growth rate of unsensitised tumours, i.e. light alone had no
effect on the tumour growth as mentioned above.
Effect ofPDTand PDTcombined with MMC on normal
tissue
Figure 5 shows the response of normal skin on mouse foot to
PDT or PDT combined with MMC. It seems that the skin
response (oedema) induced by PDT combined with 5 mg
kg-' MMC was slightly greater than that induced by PDT
alone. The response of PDT combined with 1 mgkg-' MMC
appeared to be insignificantly different from the response of
PDT alone. Moreover, it was noted that for the combination
of PDT and MMC the skin oedema peak value was delayed
for several days as compared with that of PDT alone. How-
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Table m Tumour growth time and tumour doubling time after combined or single treatment
Time to reach 5 x Doubling time in the
Injected dose of treatment volwne regrowth phase (days)
Sample drug (mgkg-') (days) mean ± s.e.m. mean ± s.e.m. Number of mice
Control 0 8.8 0.3 4.0± 0.1 8
MMC 1 8.7±0.1 4.0±0.2 5
MMC 5 12.6 0.8 3.6 ± 0.3 8
PDT Photofrin: 20 13.2 ± 0.3 4.0 ± 0.2 9
MMC + PDT MMC: 1 16.5 0.2 3.5 ± 0.4 8
Photofrin: 20
MMC + PDT MMC: 5 20.4 0.9 3.5 ± 0.4 8
Photofrin: 20
All calculations were based on growth curves for each individual mouse.
6r
5~
-/
3
2-
54 /~7
1 3 5 7
_-_ r-
11 13 15 17 19 21
Time (days)
Fugwe 4 Tumour growth curves of Balb/c nude mice bearing
WiDr colon adenocarcinoma after PDT and/or MMC treatment.
For the treatment of PDT alone, the mice were injected i.p. with
20 mg kg-' Photofrin followed 24 h later by light irradiation with
135Jcm-2 at 630nm MMC. Imgkg-' or 5mglkg-' was
administered for the treatment of MMC alone. For combined
treatment, I mg kg-' MMC was injected i.p. into the mice 12 h
after Photofrin (20mg kg-') injection and followed 12 h later by
light irradiation. Also, 5 mg kg-' MMC and 20 mgkg-' Photof-
rin were given concomitantly for 24 h and then light irradiation
with the same light condition as above. 0, Control (untreated);
0, PDT; A, MMC I mgkg-' + PDT; V, MMC I mgkg-'; O,
MMC 5 mgkg-'; x, MMC 5 mgkg-'+ PDT.
ever, the whole recovery time of the skin from oedema was
almost the same for single and combined treatments (i.e.
30-35 days). It should be mentioned that during the obser-
vations of normal tissue response to PDT or PDT combined
with MMC, besides oedema, redness in most cases and slight
scar formation in a few cases were also observed.
In the present study, we have demonstrated a significant
enhancement of the PDT anti-tumour activity by addition of
MMC. In particular, 1 mgkg-' MMC and PDT interacted
synergistically, since treatment with 1 mgkg-' MMC alone
had no effect on the WiDr tumour growth. There may be
several reasons for this effect. Firstly, our study shows that
the uptake of Photofrin by tumours is slightly increased by
MMC. Secondly, it may be due to MMC-induced accumula-
tion of the tumour cells in S-phase. Thus, we found a con-
siderable increase in the percentage of S-phase cells among
cells killed by the combined treatment as compared with
either treatment applied separately.
It has been reported that the sequence of the combination
of PDT with chemotherapeutic drugs is important (Cowled et
al., 1987; Evensen and Moan, 1988). The study of Cowled et
al. (1987) showed that doxorubicin administered with haema-
toporphyrin derivative (HPD) followed by light exposure
Days after treatment
Fige 5 Response of normal tissue (mouse foot) to the treat-
ment with PDT (0) or PDT combined with MMC (-, I mg
mg-'; A, 5 mgkg-'). Experimental conditions were as described
for Figure 4. Each point represents the average response in five
mice. T, and Tu indicate the thickness of treated (Tt) and un-
treated (T.) mouse foot.
potentiates PDT, while doxorubicin given after PDT is not as
effective. In contrast, misonidazole (MISO) given immedi-
ately after PDT potentiates the effect of PDT significantly,
while MISO administered before PDT slightly reduces the
effect of PDT (Evensen and Moan, 1988). On the other hand,
MISO given 30 min before and after PDT treatment poten-
tiates the tumour response (Gonzalez et al., 1986; Hirsch et
al., 1987). In a recent study, Baas et al. (1994) reported that
MMC given 1S min before PDT enhances RlFI tumour
response by a factor of 2, while MMC added immediately
after illumination does not increase the effect of PDT. One
possible explanation for this phenomenon is that drug access
to tumours is limited by PDT-induced vascular occlusion
when MMC is administered after illumination (Baas et al.,
1994). Also, in a murine bladder tumour model, an increased
effect of PDT by MMC administered 48 h before PDT was
observed by Cho et al. (1992). In our experiment, MMC was
given 12 h or 24 h before PDT because, under the present
experimental conditions, enhanced Photofrin uptake by the
tumours and an increased fraction of the tumour cells in
S-phase of the cell cycle were observed 12 h and 24 h after
addition of MMC. However, MMC is believed to have a half
life of 8-48 min in plasma (Dorr, 1988). Although phar-
macokinetic data regarding the retention time of MMC in
tumour tissue are not known, it may be inferred that if the
interval between administration of MMC and start of light
irradiation had been delayed up to several hours the drug
would have been almost completely cleared from tumour
tissue before the start of PDT treatment. Thus, in the present
study, activation of the cytotoxic action of MMC by the
tumour hypoxia induced by PDT can hardly explain the
results.A064mw KUVi d PDT bi.sd w1 kW
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However, there are other data which also suggest that the
effects of MMC on the cell cycle distribution may last for a
long period. It is known that the primary mechanism of
action of MMC is the formation of DNA cross-links, which
presumably inhibit DNA synthesis and block progression
through the cell cycle (Goldberg, 1%5). Our in vitro experi-
ments have demonstrated that treatment with MMC can lead
to an accumulation of WiDr cells in S and early G2 phase of
the cell cycle (Ma et al., 1992c). We have measured the
duration ofGI, S and GJ/M phases of the WiDr cell cycle in
vitro to be 13h, 12h and lOh respectively (data not pub-
lished). Most of the tumour cells (about 88%) were in GO/GI
phase at the time when MMC was injected into the mice.
When MMC acts on cells in the C0/Gl phase, their progres-
sion in the cell cycle may be significantly retarded. Moreover,
the cells are also blocked in S-phase. This may be so even if
MMC has been completely eliminated from the tumour at
this time point. This inference is in agreement with the results
of the present work. As shown in Table I, an increased
fraction of cells in S-phase was found 6-24 h after the
addition of MMC.
It has been reported that doxorubicin and methotrexate
increase uptake of HPD in Lewis lung tumours in vivo, while
in vitro doxorubicin inhibits uptake of HPD in both Raji and
Lewis lung carcinoma cells, and methotrexate has no effect
on the uptake of HPD in either cell line (Cowled et al.,
1987). The reason for this discrepancy between the in vitro
and in vivo results is not clear. In the present study, the
finding that MMC enhanced WiDr tumour uptake of Photo-
frin is consistent with our in vitro work (Ma et al., 1992a), in
which we found a 1.3- to 2.7-fold increase in the cellular
uptake of Photofrin in cultured WiDr cells after 2-8 h
incubation with MMC.
It is difficult to formulate a satisfactory hypothesis to
account for this enhancement in the tumour uptake of
Photofrin by addition of MMC. MMC has been demonstrat-
ed to be capable of generating oxygen free radicals, which
cause substantial damage to biological membranes (Trush et
al., 1982). Therefore, one may speculate that the permeability
of the tumour cell membrane or the permeability of the wall
of capillaries in the tumours may be increased by MMC.
Thus, a passive entry of Photofrin into the tumour cells may
be enhanced by the effects of MMC. We have found that
light-induced damage to the membranes of NHIK 3025 cells
leads to an increased uptake ofsensitiser into the cells (Moan
and Christensen, 1981). In addition, it has been reported that
the intracellular uptake of haematoporphyrin (HP) is related
to the position of the cells in the cell cycle. The amount of
cell-bound HP increases as the cells proceed through the cell
cycle from GI to G2JM phase and is approximately doubled
from GI to late G2 phase (Christensen and Moan, 1980). This
finding is in agreement with one of our early studies (Ma et
al., 1992a), in which the cellular uptake of Photofrin in
cultured WiDr cells was enhanced by MMC through partial
retardation of the cells in the late part of interphase and in
the M-phase of the cell cycle. In the present study, 12 h and
24 h after the administration of MMC to the mice, the
number of tumour cells in S-phase was increased by a factor
of 2.4-2.3 compared with controls (Table I). This may be
one of the reasons for the enhanced uptake of Photofrin by
tumours exposed to MMC. However, although there was no
significant increase in the fraction of S-phase cells after
30 mm administration of MMC (Table I), increased uptake
of Photofrin in the tumours was observed (Figure 3). Cer-
tainly, the influence of MMC on the uptake of Photofrin by
the tumours is not fully understood.
It is known that many therapies have a selective effect on
cells in different phases of the cell cycle. For example,
antimetabolism chemotherapeutic drugs have a specific kill-
ing effect on cells in S-phase. Cells in S-phase are more
sensitive to treatment with hyperthermia or UV irradiation
(Westra and Dewey, 1971; Han and Sinclair, 1969). CeUls in
mitosis and GI are particularly sensitive to X-rays (Dewey et
al., 1970), whereas cells near the middle and late part of
interphase show the highest sensitivity to PDT (Christensen
et al., 1981). Our previous in vitro work showed a positive
correlation between the ability of MMC to increase the
fraction of WiDr cells in S-phase and its ability to potentiate
PDT (Ma et al., 1993b). This finding is consistent with the
present results. As shown in Table II and Figure 2, after
PDT alone the tumour cells appeared to be more easily killed
in S-phase than in other phases of the cell cycle. Further-
more, when the tumour cells were retarded in S-phase by
MMC and then given PDT, the fraction of cells inactivated
in S-phase was larger than that when the tumour cells were
given PDT alone, in agreement with the fact that the anti-
tumour effect of PDT is potentiated by MMC. These data
indicate that MMC may be used clinically to retard tumour
cells in a specific phase of the cell cycle where they are
particularly sensitive to PDT and thus to optimise PDT
efficiency.
Some investigations have shown that treatment with MMC
or MISO plus light without photosensitiser produces in-
creased delay of tumour growth compared with treatment
with drug or light alone (Baas et al., 1994; Evensen and
Moan, 1988). In the present work, we did not observe an
enhanced inhibition of the tumour growth by MMC plus
light, most probably because in our experiments, 12 h and
24h after MMC administration, the drug was eliminated
from the tumour before illumination. The slight hyperther-
mia caused by the light exposure had no cytotoxic effect.
Skin photosensitivity is a factor of significant concern in
PDT. Although MMC did not reduce skin photosensitivity
(Figure 5), it was encouraging to find that no significant
increase in PDT-induced skin oedema was observed when a
low dose of MMC (1 mgkg-') was added, whereas PDT
combined with the MMC of I mg kg-' resulted in a signifi-
cantly increased inhibition of tumour growth as compared
with PDT alone (Figure 4). This result indicates that MMC
enhances PDT anti-tumour effect with some selectivity.
Obviously, systematic studies of normal tissue damage induc-
ed by PDT and by PDT in combination with chemothera-
peutic drugs are needed.
Abbreviadow PDT, photodynamic therapy; MMC, mitomycin C;
HPD, haematoporphyrtn derivatives; HP, haematoporphyrin; MISO,
misonidazole; FCM, flow cytometry.
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